390 related articles for article (PubMed ID: 33387580)
1. Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases.
Thapa K; Khan H; Sharma U; Grewal AK; Singh TG
Life Sci; 2021 Feb; 267():118975. PubMed ID: 33387580
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
Rajawat J; Shukla N; Mishra DP
Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
[TBL] [Abstract][Full Text] [Related]
4. Poly (ADP-Ribose) polymerase 1 and parthanatos in neurological diseases: From pathogenesis to therapeutic opportunities.
Xu X; Sun B; Zhao C
Neurobiol Dis; 2023 Oct; 187():106314. PubMed ID: 37783233
[TBL] [Abstract][Full Text] [Related]
5. PARP-1-Associated Pathological Processes: Inhibition by Natural Polyphenols.
Maluchenko NV; Feofanov AV; Studitsky VM
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768872
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a Low-Toxicity PARP Inhibitor as a Neuroprotective Agent for Parkinson's Disease.
Puentes LN; Lengyel-Zhand Z; Reilly SW; Mach RH
Mol Neurobiol; 2021 Aug; 58(8):3641-3652. PubMed ID: 33788167
[TBL] [Abstract][Full Text] [Related]
7. New insights of poly(ADP-ribosylation) in neurodegenerative diseases: A focus on protein phase separation and pathologic aggregation.
Liu C; Fang Y
Biochem Pharmacol; 2019 Sep; 167():58-63. PubMed ID: 31034795
[TBL] [Abstract][Full Text] [Related]
8. PARP1 inhibition alleviates injury in ARH3-deficient mice and human cells.
Mashimo M; Bu X; Aoyama K; Kato J; Ishiwata-Endo H; Stevens LA; Kasamatsu A; Wolfe LA; Toro C; Adams D; Markello T; Gahl WA; Moss J
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830864
[TBL] [Abstract][Full Text] [Related]
9. Poly (ADP-ribose) (PAR)-dependent cell death in neurodegenerative diseases.
Park H; Kam TI; Dawson TM; Dawson VL
Int Rev Cell Mol Biol; 2020; 353():1-29. PubMed ID: 32381174
[TBL] [Abstract][Full Text] [Related]
10. Poly (ADP-ribose) polymerase 1 and neurodegenerative diseases: Past, present, and future.
Hu ML; Pan YR; Yong YY; Liu Y; Yu L; Qin DL; Qiao G; Law BY; Wu JM; Zhou XG; Wu AG
Ageing Res Rev; 2023 Nov; 91():102078. PubMed ID: 37758006
[TBL] [Abstract][Full Text] [Related]
11. PARkinson's: From cellular mechanisms to potential therapeutics.
Lengyel-Zhand Z; Puentes LN; Mach RH
Pharmacol Ther; 2022 Feb; 230():107968. PubMed ID: 34391789
[TBL] [Abstract][Full Text] [Related]
12. Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases.
Pazzaglia S; Pioli C
Cells; 2019 Dec; 9(1):. PubMed ID: 31877876
[TBL] [Abstract][Full Text] [Related]
13. Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.
Martín-Guerrero SM; León J; Quiles-Perez R; Belmonte L; Martin-Oliva D; Ruiz-Extremera Á; Salmerón J; Muñoz-Gámez JA
Curr Med Chem; 2017; 24(20):2156-2173. PubMed ID: 28302009
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
[TBL] [Abstract][Full Text] [Related]
15. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
[TBL] [Abstract][Full Text] [Related]
16. PARP-DNA trapping ability of PARP inhibitors jeopardizes astrocyte viability: Implications for CNS disease therapeutics.
Sinha A; Katyal S; Kauppinen TM
Neuropharmacology; 2021 Apr; 187():108502. PubMed ID: 33631119
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders.
Chiarugi A; Moskowitz MA
J Neurochem; 2003 Apr; 85(2):306-17. PubMed ID: 12675907
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease.
Kam TI; Mao X; Park H; Chou SC; Karuppagounder SS; Umanah GE; Yun SP; Brahmachari S; Panicker N; Chen R; Andrabi SA; Qi C; Poirier GG; Pletnikova O; Troncoso JC; Bekris LM; Leverenz JB; Pantelyat A; Ko HS; Rosenthal LS; Dawson TM; Dawson VL
Science; 2018 Nov; 362(6414):. PubMed ID: 30385548
[TBL] [Abstract][Full Text] [Related]
19. The role of poly(ADP-ribose) polymerase-1 in CNS disease.
Kauppinen TM; Swanson RA
Neuroscience; 2007 Apr; 145(4):1267-72. PubMed ID: 17084037
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
Virág L; Szabó C
Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
